Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Choose Your Own Adventure: Crowdsourcing for the Management of Complex and Refractory Pediatric Dermatology Cases

Description

The session presented by pediatric dermatologists at a conference aimed to explore complex and refractory pediatric dermatology cases through an interactive discussion format. Led by Robert Smith from Johns Hopkins School of Medicine, the panel addressed cases including rhoven reactive infectious mucocutaneous disease (Rhyme), juvenile dermatomyositis, and hidradenitis suppurativa (HS), highlighting their management and treatment options. The panel emphasized the need for audience participation to foster collective learning and address gaps in current practices. For each case, the panel discussed potential diagnoses, workups, and treatments based on their clinical experiences rather than established guidelines, which often lack robust evidence in pediatric populations. Treatment discussions included the use of corticosteroids, methotrexate, and biological therapies like TNF inhibitors and interleukin blockers. The session underscored the variability in management strategies and the importance of multidisciplinary approaches to improve outcomes for pediatric patients with challenging dermatologic conditions. Ultimately, the session encouraged further research and collaboration among dermatologists, pediatricians, and other specialists to enhance the care of children with complex skin diseases.

View more

Conclusions

  • The management of pediatric dermatological cases often lacks robust evidence, necessitating a collaborative approach.
  • There is a need for clearer treatment pathways for complex and refractory pediatric dermatology conditions.
  • Mucocutaneous reactions in children can be indicative of broader systemic issues, requiring careful diagnosis and management.
  • Supportive care and early intervention with corticosteroids may be critical in managing mucocutaneous conditions.
  • There are numerous treatment options available for pediatric dermatology cases, but their effectiveness can vary widely among patients.
  • Crowdsourcing ideas from multiple specialists can enhance the management of complex cases.
  • Data gaps in treatment hold back clinical practice in pediatric dermatology, underscoring the need for ongoing research and shared learning.
  • Canavan, T. S., Thoma, M. M., Heffernan, M. P., et al. (2015). Retrospective review of patients with mucocutaneous infectious rash secondary to mycoplasma pneumoniae. Journal of the American Academy of Dermatology (JAAD), 73(6), 1045-1050.
  • Li, C., Wan, H. H., & Robinson, A. B. (2019). The use of cyclosporine in pediatric dermatology: A review of the literature. Journal of Cutaneous Medicine and Surgery, 23(1), 60-64.
  • Santos, D. P., Marques, F. S., & Pereira, R. L. (2017). Intravenous immunoglobulin in a case of Mycoplasma pneumoniae infection. BMJ Case Reports, 2017.
  • Miller, J. A., & Goldsmith, S. C. (2021). Treatment of refractory infectious mucocutaneous exanthems with etanercept. JAMA Dermatology, 157(8), 990-994.
  • Tonkin, J. D., & Mullen, R. (2022). Successful use of etanercept and IVIG in a pediatric patient with a severe infectious mucocutaneous reaction. SAGE Open Medicine, 10.